Seaport Therapeutics Inc., a clinical-stage biotechnology company focused on antidepressants and anxiety drugs, is seeking to raise $212.4 million in a US initial public offering.
Source link
Antidepressant Drugmaker Seaport Seeks $212.4 Million in US IPO
